Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
A Randomized, Open-Label Exploratory Study To Determine The Efficacy Of Different Treatment Regimens Of Pyramax® (Pyronaridine-Artesunate) In Asymptomatic Carriers Of Plasmodium Falciparum Monoinfections
Sponsor: Medicines for Malaria Venture
Listed as NCT03814616, this PHASE2 trial focuses on Malaria,Falciparum and remains ongoing. Sponsored by Medicines for Malaria Venture, it has been updated 8 times since 2018, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Jul 2019 [monthly]
Recruiting PHASE2
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medicines for Malaria Venture
- Shin Poong Pharmaceutical Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .